NovMetaPharma Co Ltd
229500
Company Profile
Business description
NovMetaPharma Co Ltd researches and develops new medicines and health supplements for metabolic diseases. The company is developing a therapeutic agent that is in Phase 2a clinical trial for Type 2 diabetes and obesity. It also develops therapeutic agents for Alzheimer’s disease, immune system diseases, osteoporosis, and non-alcoholic fatty liver diseases.
Contact
727 13, Gangnam-gu, Seoul eonju layer
Seoul
KORT: +82 25381893
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
19
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,591.60 | 112.80 | -1.46% |
| CAC 40 | 7,100.42 | 173.30 | 2.50% |
| DAX 40 | 20,280.26 | 490.64 | 2.48% |
| Dow JONES (US) | 37,615.47 | 2,930.46 | -7.23% |
| FTSE 100 | 7,910.53 | 144.45 | -1.79% |
| HKSE | 19,808.95 | 318.73 | -1.58% |
| NASDAQ | 15,254.01 | 1,296.60 | -7.83% |
| Nikkei 225 | 31,844.57 | 1,168.01 | -3.54% |
| NZX 50 Index | 11,834.74 | 56.70 | -0.48% |
| S&P 500 | 4,977.73 | 84.52 | -1.67% |
| S&P/ASX 200 | 7,403.90 | 106.10 | -1.41% |
| SSE Composite Index | 3,152.96 | 7.41 | 0.24% |